Ashu Madan, president of core client group at Religare Securities advised buying Dishman Pharma at current levels. In short-term, the stock can go up by 10-15 percent, feels Madan.
Ashu Madan, president of core client group at Religare Securities told CNBC-TV18, "Dishman Pharmaceuticals and Chemicals' numbers are decent. The way the market movement also suggest I think current price is also a better price or a good price to buy."
“In short-term one might get 10-15 percent return soon. So in any case if somebody can hold it for longer it would be better, but the current price at which it is hovering around is a good price to buy,” Madan said.